Bio-Techne Corporation
TECH
Pozycja w akcjach
#1874
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures,... Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
Cena akcji
$72.55
Ostatnia synchronizacja: 2026-10-16
Kapitalizacja rynkowa
$11.38B
Zmiana (1 dzień)
0.03%
Zmiana (1 rok)
17.27%
Kraj
US
Handel Bio-Techne Corporation (TECH)
Kategoria
Healthcare
Marża operacyjna dla Bio-Techne Corporation (TECH)
Marża operacyjna na dzień October 2026 TTM: 20.73%
Według najnowszych raportów finansowych i ceny akcji Bio-Techne Corporation, bieżąca marża operacyjna (TTM) wynosi 20.73%. Na koniec 2024 wynosiła 17.83%.
Historia marży operacyjnej dla Bio-Techne Corporation od 2000 do 2026
Marża operacyjna na koniec każdego roku
| Rok | Marża operacyjna | Zmień |
|---|---|---|
| 2026 (TTM) | 20.73% | 147.37% |
| 2025 | 8.38% | -53.00% |
| 2024 | 17.83% | -32.21% |
| 2023 | 26.30% | -1.98% |
| 2022 | 26.83% | 67.06% |
| 2021 | 16.06% | 58.85% |
| 2020 | 10.11% | -42.52% |
| 2019 | 17.59% | -16.95% |
| 2018 | 21.18% | -2.08% |
| 2017 | 21.63% | -28.33% |
| 2016 | 30.18% | -7.17% |
| 2015 | 32.51% | -27.19% |
| 2014 | 44.65% | -12.49% |
| 2013 | 51.02% | -3.44% |
| 2012 | 52.84% | -6.03% |
| 2011 | 56.23% | -3.22% |
| 2010 | 58.10% | 1.72% |
| 2009 | 57.12% | 1.91% |
| 2008 | 56.05% | 0.90% |
| 2007 | 55.55% | 3.73% |
| 2006 | 53.55% | -2.14% |
| 2005 | 54.72% | 7.25% |
| 2004 | 51.02% | 9.25% |
| 2003 | 46.70% | 15.74% |
| 2002 | 40.35% | 1.61% |
| 2001 | 39.71% | 4.80% |
| 2000 | 37.89% | 0.00% |
Marża operacyjna dla podobnych firm lub konkurentów
| Firma | Marża operacyjna | Różnica w marży operacyjnej | Kraj |
|---|---|---|---|
| 38.59% | -98.14% |
US
|
|
| -149.01% | -107.19% |
US
|
|
| 25.57% | -98.77% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -98.61% |
NL
|
Czym jest marża operacyjna firmy?
Marża operacyjna to kluczowy wskaźnik do oceny rentowności firmy. Wyższe marże operacyjne są zazwyczaj korzystniejsze, ponieważ pokazują, że firma może sprzedawać swoje produkty lub usługi znacznie drożej niż koszty ich produkcji. Oblicza się ją, dzieląc zysk firmy przez jej przychody.